Boston Pharmaceuticals

Boston Pharmaceuticals company information, Employees & Contact Information

Transforming the right molecules into the best medicines™ Boston Pharmaceuticals acquires and transforms innovative molecules into differentiated medicines that improve patients’ lives. We have rapidly built a portfolio of high-value candidates across multiple therapeutic areas and are actively seeking additional programs for our diverse pipeline.

Company Details

Employees
83
Address
55 Cambridge Parkway,
Email
in****@****als.com
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
Keywords
jobs.
HQ
Cambridge, MA
Looking for a particular Boston Pharmaceuticals employee's phone or email?

Boston Pharmaceuticals Questions

News

Boston Pharmaceuticals to Present the Effect of Efimosfermin Alfa on Collagen Biomarkers in Patients with F2 and F3 MASH at EASL Congress 2025 - Business Wire

Boston Pharmaceuticals to Present the Effect of Efimosfermin Alfa on Collagen Biomarkers in Patients with F2 and F3 MASH at EASL Congress 2025 Business Wire

Boston Pharmaceuticals to Present State-of-the-Art Lecture and Poster for Once-monthly Efimosfermin Alfa at Digestive Disease Week® 2025 - Yahoo Finance

Boston Pharmaceuticals to Present State-of-the-Art Lecture and Poster for Once-monthly Efimosfermin Alfa at Digestive Disease Week® 2025 Yahoo Finance

GSK pays $1.2B upfront for Boston Pharmaceuticals' lead liver disease drug - Fierce Biotech

GSK pays $1.2B upfront for Boston Pharmaceuticals' lead liver disease drug Fierce Biotech

Pieris Pharmaceuticals and Boston Pharmaceuticals Enter into an Exclusive Worldwide Product License for PRS-342, a 4-1BB/GPC3 Immuno-Oncology Bispecific - ACCESS Newswire

Pieris Pharmaceuticals and Boston Pharmaceuticals Enter into an Exclusive Worldwide Product License for PRS-342, a 4-1BB/GPC3 Immuno-Oncology Bispecific ACCESS Newswire

Boston Pharmaceuticals to Announce Positive Phase 2 Data on Efimosfermin Alfa (BOS-580) in F2/F3 MASH During Late-Breaking Oral Presentation at AASLD 2024, The Liver Meeting - Business Wire

Boston Pharmaceuticals to Announce Positive Phase 2 Data on Efimosfermin Alfa (BOS-580) in F2/F3 MASH During Late-Breaking Oral Presentation at AASLD 2024, The Liver Meeting Business Wire

Boston Pharmaceuticals Appoints Juan Carlos Lopez-Talavera, MD, PhD, as Acting Chief Medical Officer - citybiz

Boston Pharmaceuticals Appoints Juan Carlos Lopez-Talavera, MD, PhD, as Acting Chief Medical Officer citybiz

GSK to acquire efimosfermin, a phase III-ready potential best-in-class specialty medicine to treat and prevent progression of steatotic liver disease (SLD) - Business Wire

GSK to acquire efimosfermin, a phase III-ready potential best-in-class specialty medicine to treat and prevent progression of steatotic liver disease (SLD) Business Wire

Boston Pharmaceuticals Licenses Potential NASH Treatment from Novartis - BioSpace

Boston Pharmaceuticals Licenses Potential NASH Treatment from Novartis BioSpace

Boston Pharmaceuticals Appoints Dr. Sophie Kornowski as Chair of its Board of Directors and Acting Chief Executive - citybiz

Boston Pharmaceuticals Appoints Dr. Sophie Kornowski as Chair of its Board of Directors and Acting Chief Executive citybiz

Novartis licenses three novel anti-infective programs to Boston Pharmaceuticals - Novartis

Novartis licenses three novel anti-infective programs to Boston Pharmaceuticals Novartis

Former Sanofi chief to launch Boston Pharmaceuticals with $600m - The Boston Globe

Former Sanofi chief to launch Boston Pharmaceuticals with $600m The Boston Globe

Boston Pharmaceuticals raids Novartis' store again, nabbing a new NASH asset - Fierce Biotech

Boston Pharmaceuticals raids Novartis' store again, nabbing a new NASH asset Fierce Biotech

Boston Pharmaceuticals Announces Former NIH Director, Dr. Elias Zerhouni, As the New Chair of Its Board of Directors - Business Wire

Boston Pharmaceuticals Announces Former NIH Director, Dr. Elias Zerhouni, As the New Chair of Its Board of Directors Business Wire

Boston Pharmaceuticals nabs Novartis veteran as new CMO - Fierce Biotech

Boston Pharmaceuticals nabs Novartis veteran as new CMO Fierce Biotech

Boston Pharmaceuticals Presents Data at NASH-TAG 2024 Demonstrating Low Immunogenicity Over Time With Long-acting FGF21 Analogue, BOS-580, for MASH - Business Wire

Boston Pharmaceuticals Presents Data at NASH-TAG 2024 Demonstrating Low Immunogenicity Over Time With Long-acting FGF21 Analogue, BOS-580, for MASH Business Wire

Top Boston Pharmaceuticals Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant